What It Is
Chonluten is a short synthetic tripeptide made from glutamic acid, aspartic acid, and glycine, commonly written Glu-Asp-Gly or EDG. PubChem lists it as CID 194641, with molecular formula C11H17N3O8 and a molecular weight of about 319 g/mol.[1] It is sometimes referenced by the shorthand T-34. Like Cardiogen and Cartalax, it falls into the peptide bioregulator research category, and it is discussed mainly in relation to lung and bronchial biology because the sequence has been described as derived from bronchial epithelial cells — a description that establishes a research rationale, not a proven respiratory benefit.[2]
How It Works
The most directly relevant published study exposed THP-1 monocyte and macrophage cells — a standard immune-cell line, not lung tissue — to Chonluten alongside a bacterial inflammatory stimulus (lipopolysaccharide). Researchers reported effects on tumor necrosis factor and interleukin-6 release, STAT and ERK1/2 signaling, and cell-adhesion markers, suggesting Chonluten may modulate inflammatory signaling in immune cells under laboratory conditions.[2] Broader short-peptide literature proposes that such sequences may interact with DNA, histones, or chromatin to influence gene expression, but this is a general theoretical framework rather than Chonluten-specific proof, and cytokine changes in a cell line are a long way from demonstrated improvements in lung function or symptoms in people.[3]
What the Research Shows
Beyond the THP-1 immune-cell study, no peer-reviewed human trials evaluating Chonluten for asthma, COPD, bronchitis, pulmonary fibrosis, or any other respiratory condition were identified, nor was a registered clinical-trial program found on ClinicalTrials.gov.[15] A related but distinct peptide, Bronchogen (AEDL), has separate published research on bronchial epithelial gene expression, but that evidence belongs to a different compound and should not be attributed to Chonluten.[4] In short, the entire direct evidence base for Chonluten is a single line of in vitro immune-cell experiments — useful for generating hypotheses, but far short of what would be needed to support a respiratory-health claim in humans.
Safety & Side Effects
No human adverse-event data exist for Chonluten because no clinical trials have been conducted. The in vitro study measured cell-signaling changes, not safety outcomes, so it cannot be used to infer that the compound is safe in people.[2] More broadly, therapeutic peptides can carry immunogenicity risks tied to manufacturing impurities, and unapproved or compounded peptide products carry additional risks of contamination or inaccurate potency.[12][14] Pregnancy, breastfeeding, pediatric use, and use by people with active respiratory or autoimmune disease are entirely unstudied for Chonluten specifically.
Regulatory Status
No FDA-approved Chonluten product, labeled indication, or approved dosage was identified in the FDA's Orange Book, Drugs@FDA, or FDA label-search resources.[9][10][11] Chonluten is not an approved medicine in the United States for any respiratory or other condition. FDA has separately noted that a product's availability online, or its listing with a National Drug Code, does not by itself indicate FDA approval — a distinction relevant to any Chonluten product marketed for personal use.[18]